Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells.

[1]  S. Meltzer,et al.  Thapsigargin resistance in human prostate cancer cells , 2006, Cancer.

[2]  P. Schuff-Werner,et al.  Double transfection improves small interfering RNA‐induced thrombin receptor (PAR‐1) gene silencing in DU 145 prostate cancer cells , 2004, FEBS letters.

[3]  C. Toyoshima,et al.  Specific Structural Requirements for the Inhibitory Effect of Thapsigargin on the Ca2+ ATPase SERCA* , 2004, Journal of Biological Chemistry.

[4]  H. Lilja,et al.  Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. , 2003, Journal of the National Cancer Institute.

[5]  J. Montalbano,et al.  Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis , 2003, Oncogene.

[6]  W. El-Deiry,et al.  Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway , 2002, Oncogene.

[7]  P. S. Pedersen,et al.  The Sarco/Endoplasmic Reticulum Calcium-ATPase 2b Is an Endoplasmic Reticulum Stress-inducible Protein* , 2000, The Journal of Biological Chemistry.

[8]  V. Dixit,et al.  Characterization of Calcium Release-activated Apoptosis of LNCaP Prostate Cancer Cells* , 2000, The Journal of Biological Chemistry.

[9]  M. Yu,et al.  Effects of various amino acid 256 mutations on sarcoplasmic/endoplasmic reticulum Ca2+ ATPase function and their role in the cellular adaptive response to thapsigargin. , 1999, Archives of biochemistry and biophysics.

[10]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Rishi,et al.  Gene amplification and transcriptional upregulation of the sarco/endoplasmic reticulum Ca2+ transport ATPase in thapsigargin-resistant hamster smooth muscle cells. , 1998, Nucleic acids research.

[12]  A. Rishi,et al.  Specific Substitutions at Amino Acid 256 of the Sarcoplasmic/Endoplasmic Reticulum Ca2+ Transport ATPase Mediate Resistance to Thapsigargin in Thapsigargin-resistant Hamster Cells* , 1998, The Journal of Biological Chemistry.

[13]  L. Jones,et al.  Functional Co-expression of the Canine Cardiac Ca2+Pump and Phospholamban in Spodoptera frugiperda (Sf21) Cells Reveals New Insights on ATPase Regulation* , 1997, The Journal of Biological Chemistry.

[14]  S. Bates,et al.  Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P‐glycoprotein or MRP overexpression , 1997, Journal of cellular biochemistry.

[15]  T. McCormick,et al.  Mouse Lymphoma Cells Destined to Undergo Apoptosis in Response to Thapsigargin Treatment Fail to Generate a Calcium-mediated grp78/grp94 Stress Response* , 1997, The Journal of Biological Chemistry.

[16]  A. Campbell,et al.  Induction of calreticulin expression in HeLa cells by depletion of the endoplasmic reticulum Ca2+ store and inhibition of N-linked glycosylation. , 1996, The Biochemical journal.

[17]  M. Berridge,et al.  Capacitative calcium entry. , 1995, The Biochemical journal.

[18]  M. F. Schneider,et al.  Direct Involvement of Intracellular Ca Transport ATPase in the Development of Thapsigargin Resistance by Chinese Hamster Lung Fibroblasts (*) , 1995, The Journal of Biological Chemistry.

[19]  G. Dubyak,et al.  Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Gutheil,et al.  Alterations in Ca2+ transport ATPase and P-glycoprotein expression can mediate resistance to thapsigargin. , 1994, The Journal of biological chemistry.

[21]  X. Cao,et al.  Transactivation of the grp78 promoter by Ca2+ depletion. A comparative analysis with A23187 and the endoplasmic reticulum Ca(2+)-ATPase inhibitor thapsigargin. , 1993, The Journal of biological chemistry.

[22]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[23]  S. Mirski,et al.  Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. , 1991, Cancer research.

[24]  J. Putney.  Capacitative calcium entry revisited. , 1990, Cell calcium.

[25]  A. Fojo,et al.  Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. , 1990, The Journal of biological chemistry.

[26]  J. Lytton,et al.  Molecular cloning of cDNAs from human kidney coding for two alternatively spliced products of the cardiac Ca2+-ATPase gene. , 1988, The Journal of biological chemistry.

[27]  S. Orrenius,et al.  2,5‐Di(tert‐butyl)‐1,4‐benzohydroquinone — a novel inhibitor of liver microsomal Ca2+ sequestration , 1987, FEBS letters.

[28]  J. Endicott,et al.  Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance , 1986, Nature.

[29]  D. Housman,et al.  Isolation and expression of a complementary DNA that confers multidrug resistance , 1986, Nature.

[30]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.